ACAD - ACADIA Pharmaceuticals Inc.
NEXT EARNINGS:
Feb 25, 2026
(today)
EPS Est: $0.12
|
Rev Est: $292.5M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$34.78
DETAILS
HIGH:
$40.00
LOW:
$29.00
MEDIAN:
$35.00
CONSENSUS:
$34.78
UPSIDE:
41.44%
Market Cap:
4.16B
Volume:
1,433,725
Avg Volume:
1,524,372
52 Week Range:
13.4-28.35
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.66
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
653
IPO Date:
2004-05-27
EPS (TTM):
1.37
P/E Ratio:
13.43
Revenue (TTM):
957.80M
Total Assets:
1.19B
Total Debt:
51.99M
Cash & Equiv:
319.59M
Rev Growth (5Y):
23.1%
EPS Growth (5Y):
9.4%
FCF Growth (5Y):
N/A
ROCE:
10.6%
Debt/Equity:
0.07
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-05 | $0.26 | $0.14 | +85.7% | $278.6M | $292.6M | -4.8% |
| 2025-08-06 | $0.16 | $0.14 | +14.3% | $264.6M | $262.0M | +1.0% |
| 2025-05-07 | $0.11 | $0.10 | +10.0% | $244.3M | $239.0M | +2.2% |
| 2025-02-26 | $0.17 | $0.13 | +30.8% | $259.6M | $273.0M | -4.9% |
| 2024-11-06 | $0.20 | $0.14 | +42.9% | $250.4M | $282.9M | -11.5% |
| 2024-08-06 | $0.20 | $0.18 | +11.1% | $242.0M | $235.4M | +2.8% |
| 2024-05-08 | $0.10 | $0.05 | +100.0% | $205.8M | $208.3M | -1.2% |
| 2024-02-27 | $0.28 | $0.30 | -6.7% | $231.0M | $223.8M | +3.2% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 957.80M | 726.44M | 517.24M | 484.14M | 441.75M | 339.08M | 223.81M | 124.90M | 17.33M | 61,000 | 120,000 | 1.15M |
| Net Income | 226.45M | (61.29M) | (215.97M) | (167.87M) | (281.58M) | (235.26M) | (245.19M) | (289.40M) | (271.39M) | (164.44M) | (92.47M) | (37.95M) |
| EPS | 1.37 | -0.37 | -1.34 | -1.05 | -1.79 | -1.60 | -1.94 | -2.36 | -2.34 | -1.63 | -0.95 | -0.44 |
| Total Assets | 1.19B | 748.96M | 587.81M | 700.12M | 782.62M | 783.18M | 540.20M | 384.51M | 561.15M | 221.90M | 325.46M | 189.12M |
| Total Debt | 51.99M | 57.20M | 62.00M | 64.43M | 49.55M | 9.79M | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equivalents | 319.59M | 188.66M | 114.85M | 147.44M | 326.03M | 189.68M | 134.76M | 69.42M | 163.62M | 102.14M | 61.85M | 11.71M |
| Operating Cash Flow | 157.72M | 16.70M | (114.03M) | (125.66M) | (136.17M) | (151.13M) | (167.47M) | (217.86M) | (210.41M) | (121.80M) | (66.43M) | (31.77M) |
| Free Cash Flow | 157.20M | (23.35M) | (114.03M) | (126.78M) | (143.75M) | (152.26M) | (169.62M) | (218.67M) | (219.91M) | (123.94M) | (66.61M) | (32.39M) |
| FCF per Share | 0.95 | -0.14 | -0.71 | -0.79 | -0.91 | -1.03 | -1.34 | -1.78 | -1.90 | -1.23 | -0.68 | -0.38 |
| Book Value | 732.79M | 431.75M | 400.41M | 540.89M | 627.01M | 699.13M | 479.08M | 335.29M | 518.41M | 199.76M | 309.49M | 182.13M |
| Cash & ST Investments | 755.99M | 438.87M | 416.82M | 520.71M | 631.96M | 697.43M | 473.52M | 341.34M | 529.04M | 215.13M | 322.49M | 185.79M |
| ROC Equity | 0.31 | -0.14 | -0.54 | -0.31 | -0.45 | -0.34 | -0.51 | -0.86 | -0.52 | -0.82 | -0.30 | -0.21 |